Five tech business trends to watch in 2021
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →‘Golden age of biotechnology’ comes to Conejo Valley
Westlake Village BioPartners has launched two new funds worth a total of $500 million, bringing the total raised by the firm to more than $820 million since it was founded in 2018.
Read More →Westlake Village BioPartners puts $500 million into new venture funds
Westlake Village BioPartners, a venture capital firm focused on biotech startups in the Conejo Valley and the rest of greater Los Angeles, launched two new funds Dec. 15 worth a total of $500 million. The first fund is $70 million and will be used for Series B or later financing into companies that Westlake Village Read More →
Read More →MannKind makes $12.5M pharma buy
MannKind Corp., a biotech company based in Westlake Village, announced Dec. 7 that it has acquired a QrumPharma, a privately held biotech company, in a $12.5 million deal. MannKind has purchased all outstanding capital stock of QrumPharma for $3.5 million in cash and just over 3 million shares of MannKind common stock. At MannKind’s stock Read More →
Read More →Amgen joins new cooperative trials for COVID treatment
With COVID-19 continuing to surge across the globe, a coalition of pharmaceutical companies including Thousand Oaks-based Amgen has announced a joint trial for new coronavirus treatments. Amgen, along with Takeda and UCB, are now collaborating to study methods of treatment for patients who are hospitalized due to COVID-19, the three companies announced. The trial enrolled Read More →
Read More →Amgen beats expectations in Q3 earnings report
Amgen, one of the biggest biopharmaceutical companies in the world, continued to see growth in the third quarter of 2020, despite the COVID-19 pandemic. The Thousand Oaks-based company saw total revenue of $6.4 billion for the quarter, up 12 percent from the third quarter of 2019. Earnings per share increased 5 percent to $3.43. Both Read More →
Read More →Arcutis shares up on news of public, private offerings
Arcutis Biotherapeutics saw a 15 percent rise in its share price after it said Sept. 29 that it will offer 4 million shares to the public and sell another $35 million in stock to an affiliate of one of its directors. Arcutis closed at $31.04, a gain of $4.28 after it announced the dual track Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
